Menu

Quarterly result update

ICICI Prudential Life Insurance Q1 FY23 result update

ICICI Prudential Life Insurance Q1 update.

ICICI Prudential Life Insurance Q1 FY23 result update.

ICICI Prudential Life Insurance Company posted a net profit of Rs. 156Cr. in Q1FY23, on Saturday, compared to a loss of Rs.186Cr. in Q1FY22. The growth was primarily on account of lower claims and provisions due to Covid-19.

The AUM for the company grew by 3.1% to Rs. 2, 30,072Cr. The 13-month persistency ratio improved to 85.5% while 43-month ratio increased from 63.4% to 65.0% in FY23. As per the Management, the company 4P’s strategy guided by elements like Premium growth, Protection focus, Persistency improvement, and Productivity enhancement is on track with a target of doubling the FY19 value of the new business (VNB).

The business reported a negative investment income of Rs.6,884 Cr. in Q1FY23 versus a positive investment income of Rs.9,0609 Cr. in Q1 FY22. The total expenses incurred increased by 16.1% to Rs.1,411 Cr. in Q1 FY23 from Rs.1215 Cr. in FY22. The APE (Annual Premium Equivalent) witnessed a growth of 24.7% o Rs.1,520Cr. compared to Rs.1,219Cr. in FY22. The VNB was at Rs.471Cr a growth of 31% in FY23 which was previous at 28.0%, on account of a shift in the underlying product mix.

The business premium stood at Rs.3184 Cr. with a growth of 24.4% as compared to Rs.2,559Cr. The annuity APE rose to Rs.98Cr. in FY23 with robust growth of Rs.69% which was at Rs.58Cr. Savings APE was at Rs.892Cr. to Rs.1092Cr for the same period.
The company’s TWRP ratio (total weighted received premium) for savings business and the total cost was at 16.9% and 23.8% respectively. The APE of new business is significant and expenses will not affect margins. The ICICI bank-backed insurance company has a debt-equity mix of 54:46 as of 30 June 2022. The company has zero NPA with 98% of debt instruments being AAA rated and treasury bonds. The claims and benefits payout decreased by 2.8% to Rs.5,512Cr. in FY23.

The Company strives to target untouched customer segments and expand in distribution footprint which enabled them to maintain its market leader position and acquired a market share of 15.8% in Q1 FY23. The net worth is at Rs.9,053 Cr and a solvency ratio of 203.6% against the regulatory requirement of 150%. ICICI Bank and Prudential Corporation holdings promote ICICI Prudential Life Insurance.

The continued supply chain management, ongoing geopolitical crisis, spike in commodity prices, the surge in inflation, and net outflows from the capital market all the factors have directly affected the unit link business. The scrip closed at Rs. 520.55 on Monday, up by 0.67% or 3.45 points. The market cap of the company is Rs.74,246Cr. It touched an intraday high of Rs.527.55 and a low of Rs.514.30.

 

 

Indigo to “rationalise” salaries of technicians following mass sick leave.

Loan growth, higher margins, and lower costs to drive bank bottom lines in Q1.

NBFCs and HFCs securitization volumes almost doubled.

Raymond spins decent yarn this quarter, meets expectations

Raymond spins decent yarn this quarter, meets expectations

Raymond Ltd is a diversified conglomerate with its presence in Textile & Apparels, FMCG, Auto Components, Engineering and Real Estate sector. The company is one of the largest exclusive retail...
Tata Global Beverages reported subdued Q4FY19 quarter

Tata Global Beverages reported subdued Q4FY19 quarter

Tata Global Beverages Ltd is the world's second largest tea company incorporated in the year 1964. It is a global beverage brand having a presence in over 40 countries. The...
Q2FY19 Results, Cipla Ltd. posted Rs 367 crores net profit

Q2FY19 Results, Cipla Ltd. posted Rs 367 crores net profit

Cipla Ltd is one of the leading Indian pharmaceutical company. It was incorporated in the year 1935. The company primarily focuses on its complex generics business and deepening its product...
Equity Right Lupin Ltd

Q2FY19 Results, Lupin Ltd. posted Rs 266 crores net profit

Lupin Ltd is a multinational pharmaceutical company, incorporated in the year 1968. It is the eighth-largest generic pharmaceutical company in terms of revenue globally. The company’s key business areas are...
J B Chemicals and Pharmaceuticals Limited  Q1 FY23 Result Updates.

Q2FY19 Results, Aurobindo Pharma Ltd. posted Rs 611.40 crores net profit

Aurobindo Pharma Limited is a fully integrated pharmaceutical company, incorporated in the year 1986. The Company manufactures Generic pharmaceutical, Active Pharmaceuticals Ingredients (API), Formulation drugs and speciality products. The companies...